Evidence map›Paper›PMID 36399462›Full record

ArticlePloS one2022

Diabetes-free survival among living kidney donors and non-donors with obesity: A longitudinal cohort study.

A Cozette Killian, Rhiannon D Reed, M Chandler McLeod, Paul A MacLennan, Vineeta Kumar, Sydney E Pittman, Andrew G Maynor, Luke A Stanford, Gavin A Baker, Carrie A Schinstock and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

A Cozette KillianComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.ORCID 0000-0002-1364-2112
Rhiannon D ReedComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.
M Chandler McLeodComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Paul A MacLennanComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Vineeta KumarComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Sydney E PittmanComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Andrew G MaynorComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Luke A StanfordComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Gavin A BakerComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Carrie A SchinstockDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, United States of America.
John R SilkensenDepartment of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, United States of America.
Garrett R RollDivision of Transplant, Department of Surgery, University of California San Francisco, San Francisco, CA, United States of America.
Dorry L SegevDepartment of Surgery, New York University Grossman School of Medicine, New York, New York, United States of America.
Babak J OrandiComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Cora E LewisDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, United States of America.ORCID 0000-0002-2301-5796
Jayme E LockeComprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL, United States of America.ORCID 0000-0002-0220-8716
University of Alabama at Birmingham · USHennepin County Medical Center · USMayo Clinic · USNew York University · USUniversity of California, San Francisco · US

Funding

CKD Risk Prediction among Obese Living Kidney DonorsR01DK113980 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LOCKE, JAYME ELIZABETH · 2018 to 2022
$3.4M
NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100005GNHLBI NIH HHS HHSN268201100005INHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007INHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100008INHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100009INHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100011INHLBI NIH HHS HHSN268201100012CNHLBI NIH HHS HHSN268201800003INHLBI NIH HHS HHSN268201800004INHLBI NIH HHS HHSN268201800005INHLBI NIH HHS HHSN268201800006INHLBI NIH HHS HHSN268201800007INIDDK NIH HHS R01 DK113980
6 · The paper itself

Abstract

backgroundApproval of living kidney donors (LKD) with end-stage kidney disease (ESKD) risk factors, such as obesity, has increased. While lifetime ESKD development data are lacking, the study of intermediate outcomes such as diabetes is critical for LKD safety. Donation-attributable diabetes risk among persons with obesity remains unknown. The purpose of this study was to evaluate 10-year diabetes-free survival among LKDs and non-donors with obesity.

methodsThis longitudinal cohort study identified adult, LKDs (1976-2020) from 42 US transplant centers and non-donors from the Coronary Artery Risk Development in Young Adults (1985-1986) and the Atherosclerosis Risk in Communities (1987-1989) studies with body mass index ≥30 kg/m2. LKDs were matched to non-donors on baseline characteristics (age, sex, race, body mass index, systolic and diastolic blood pressure) plus diabetes-specific risk factors (family history of diabetes, impaired fasting glucose, smoking history). Accelerated failure time models were utilized to evaluate 10-year diabetes-free survival.

findingsAmong 3464 participants, 1119 (32%) were LKDs and 2345 (68%) were non-donors. After matching on baseline characteristics plus diabetes-specific risk factors, 4% (7/165) LKDs and 9% (15/165) non-donors developed diabetes (median follow-up time 8.5 (IQR: 5.6-10.0) and 9.1 (IQR: 5.9-10.0) years, respectively). While not significant, LKDs were estimated to live diabetes-free 2 times longer than non-donors (estimate 1.91; 95% CI: 0.79-4.64, p = 0.15).

conclusionsLKDs with obesity trended toward living longer diabetes-free than non-donors with obesity, suggesting within the decade following donation there was no increased diabetes risk among LKDs. Further work is needed to evaluate donation-attributable diabetes risk long-term.

Indexed as

Diabetes MellitusKidney Failure, ChronicKidney TransplantationCohort StudiesHumansLiving DonorsLongitudinal StudiesObesityYoung Adult

Identifiers

PMID36399462
PMCPMC9674148
OpenAlexW4309307023

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.